Compare PLXS & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | OCUL |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 1986 | 2014 |
| Metric | PLXS | OCUL |
|---|---|---|
| Price | $154.26 | $11.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $160.00 | $22.56 |
| AVG Volume (30 Days) | 192.3K | ★ 3.1M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.11 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $4,032,966,000.00 | $55,783,000.00 |
| Revenue This Year | $10.99 | N/A |
| Revenue Next Year | $7.02 | $11.96 |
| P/E Ratio | $24.77 | ★ N/A |
| Revenue Growth | ★ 1.82 | N/A |
| 52 Week Low | $103.43 | $5.79 |
| 52 Week High | $172.89 | $16.44 |
| Indicator | PLXS | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 37.95 |
| Support Level | $149.73 | $10.92 |
| Resistance Level | $158.18 | $13.06 |
| Average True Range (ATR) | 3.91 | 0.51 |
| MACD | -0.18 | -0.24 |
| Stochastic Oscillator | 68.25 | 15.63 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.